830 related articles for article (PubMed ID: 31076365)
61. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.
Petrylak DP; de Wit R; Chi KN; Drakaki A; Sternberg CN; Nishiyama H; Castellano D; Hussain SA; Fléchon A; Bamias A; Yu EY; van der Heijden MS; Matsubara N; Alekseev B; Necchi A; Géczi L; Ou YC; Coskun HS; Su WP; Bedke J; Gakis G; Percent IJ; Lee JL; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; Garcia Del Muro X; Rodriguez-Vida A; Cicin I; Harputluoglu H; Tagawa ST; Vaishampayan U; Aragon-Ching JB; Hamid O; Liepa AM; Wijayawardana S; Russo F; Walgren RA; Zimmermann AH; Hozak RR; Bell-McGuinn KM; Powles T;
Lancet Oncol; 2020 Jan; 21(1):105-120. PubMed ID: 31753727
[TBL] [Abstract][Full Text] [Related]
62. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
[TBL] [Abstract][Full Text] [Related]
63. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.
Zhou C; Chen G; Huang Y; Zhou J; Lin L; Feng J; Wang Z; Shu Y; Shi J; Hu Y; Wang Q; Cheng Y; Wu F; Chen J; Lin X; Wang Y; Huang J; Cui J; Cao L; Liu Y; Zhang Y; Pan Y; Zhao J; Wang L; Chang J; Chen Q; Ren X; Zhang W; Fan Y; He Z; Fang J; Gu K; Dong X; Zhang T; Shi W; Zou J;
Lancet Respir Med; 2021 Mar; 9(3):305-314. PubMed ID: 33347829
[TBL] [Abstract][Full Text] [Related]
64. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
[TBL] [Abstract][Full Text] [Related]
65. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Nakagawa K; Garon EB; Seto T; Nishio M; Ponce Aix S; Paz-Ares L; Chiu CH; Park K; Novello S; Nadal E; Imamura F; Yoh K; Shih JY; Au KH; Moro-Sibilot D; Enatsu S; Zimmermann A; Frimodt-Moller B; Visseren-Grul C; Reck M;
Lancet Oncol; 2019 Dec; 20(12):1655-1669. PubMed ID: 31591063
[TBL] [Abstract][Full Text] [Related]
66. A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).
Cognetti F; Bagnato A; Colombo N; Savarese A; Scambia G; Sehouli J; Wimberger P; Sorio R; Harter P; Mari E; McIntosh S; Nathan F; Pemberton K; Baumann K
Gynecol Oncol; 2013 Jul; 130(1):31-7. PubMed ID: 23234805
[TBL] [Abstract][Full Text] [Related]
67. Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
Del Carmen MG; Supko JG; Horick NK; Rauh-Hain JA; Clark RM; Campos SM; Krasner CN; Atkinson T; Birrer MJ
Cancer; 2016 Nov; 122(21):3297-3306. PubMed ID: 27421044
[TBL] [Abstract][Full Text] [Related]
68. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
[TBL] [Abstract][Full Text] [Related]
69. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
70. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
Oza AM; Matulonis UA; Malander S; Hudgens S; Sehouli J; Del Campo JM; Berton-Rigaud D; Banerjee S; Scambia G; Berek JS; Lund B; Tinker AV; Hilpert F; Vázquez IP; D'Hondt V; Benigno B; Provencher D; Buscema J; Agarwal S; Mirza MR
Lancet Oncol; 2018 Aug; 19(8):1117-1125. PubMed ID: 30026000
[TBL] [Abstract][Full Text] [Related]
71. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial.
Xu RH; Zhang Y; Pan H; Feng J; Zhang T; Liu T; Qin Y; Qin S; Yin X; Liu B; Ba Y; Yang N; Voon PJ; Tanasanvimon S; Zhou C; Zhang WL; Shen L
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1015-1024. PubMed ID: 34626550
[TBL] [Abstract][Full Text] [Related]
72. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
73. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
Coleman RL; Fleming GF; Brady MF; Swisher EM; Steffensen KD; Friedlander M; Okamoto A; Moore KN; Efrat Ben-Baruch N; Werner TL; Cloven NG; Oaknin A; DiSilvestro PA; Morgan MA; Nam JH; Leath CA; Nicum S; Hagemann AR; Littell RD; Cella D; Baron-Hay S; Garcia-Donas J; Mizuno M; Bell-McGuinn K; Sullivan DM; Bach BA; Bhattacharya S; Ratajczak CK; Ansell PJ; Dinh MH; Aghajanian C; Bookman MA
N Engl J Med; 2019 Dec; 381(25):2403-2415. PubMed ID: 31562800
[TBL] [Abstract][Full Text] [Related]
74. Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.
Monk BJ; Toita T; Wu X; Vázquez Limón JC; Tarnawski R; Mandai M; Shapira-Frommer R; Mahantshetty U; Del Pilar Estevez-Diz M; Zhou Q; Limaye S; Godinez FJR; Oppermann Kussler C; Varga S; Valdiviezo N; Aoki D; Leiva M; Lee JY; Sulay R; Kreynina Y; Cheng WF; Rey F; Rong Y; Ke G; Wildsmith S; Lloyd A; Dry H; Tablante Nunes A; Mayadev J
Lancet Oncol; 2023 Dec; 24(12):1334-1348. PubMed ID: 38039991
[TBL] [Abstract][Full Text] [Related]
75. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Dhillon S
BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
[TBL] [Abstract][Full Text] [Related]
76. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Gould N; Sill MW; Mannel RS; Thaker PH; Disilvestro P; Waggoner S; Yamada SD; Armstrong DK; Wenzel L; Huang H; Fracasso PM; Walker JL
Gynecol Oncol; 2012 Apr; 125(1):54-8. PubMed ID: 22155262
[TBL] [Abstract][Full Text] [Related]
77. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
Hodi FS; Chesney J; Pavlick AC; Robert C; Grossmann KF; McDermott DF; Linette GP; Meyer N; Giguere JK; Agarwala SS; Shaheen M; Ernstoff MS; Minor DR; Salama AK; Taylor MH; Ott PA; Horak C; Gagnier P; Jiang J; Wolchok JD; Postow MA
Lancet Oncol; 2016 Nov; 17(11):1558-1568. PubMed ID: 27622997
[TBL] [Abstract][Full Text] [Related]
78. AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial.
Heitz F; Marth C; Henry S; Reuss A; Cibula D; Gaba Garcia L; Colombo N; Schmalfeld B; de Gregorio N; Wimberger P; Hasenburg A; Sehouli J; Gropp-Meier M; Schouten PC; Hahnen E; Hauke J; Polleis S; Harter P
Int J Gynecol Cancer; 2023 Dec; 33(12):1966-1969. PubMed ID: 37935524
[TBL] [Abstract][Full Text] [Related]
79. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.
Ledermann JA; Embleton AC; Raja F; Perren TJ; Jayson GC; Rustin GJS; Kaye SB; Hirte H; Eisenhauer E; Vaughan M; Friedlander M; González-Martín A; Stark D; Clark E; Farrelly L; Swart AM; Cook A; Kaplan RS; Parmar MKB;
Lancet; 2016 Mar; 387(10023):1066-1074. PubMed ID: 27025186
[TBL] [Abstract][Full Text] [Related]
80. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.
Gershenson DM; Miller A; Brady WE; Paul J; Carty K; Rodgers W; Millan D; Coleman RL; Moore KN; Banerjee S; Connolly K; Secord AA; O'Malley DM; Dorigo O; Gaillard S; Gabra H; Slomovitz B; Hanjani P; Farley J; Churchman M; Ewing A; Hollis RL; Herrington CS; Huang HQ; Wenzel L; Gourley C
Lancet; 2022 Feb; 399(10324):541-553. PubMed ID: 35123694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
